Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD

Bibliography

• Global initiative for chronic Obstructive Lung Disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013Feb13.pdf
   Google Scholar
• Gan WQ, Man SF, Senthilseilvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80
   PubMed Web of Science ®Google Scholar
• Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013;107:1376-84
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes. The Future of COPD. Am J Respir Crit Care Med 2010;182:598-604
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson H, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008;31:869-73
   PubMed Web of Science ®Google Scholar
• Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010;7:32-43
   PubMedGoogle Scholar
• The SPIROMICS Investigators. Design of the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). Thorax 2013; In Press
   Web of Science ®Google Scholar
• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(5 Suppl):398S-401S
   PubMed Web of Science ®Google Scholar
• Anzueto A, Sethi S, Martinez F. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:554-64
   PubMedGoogle Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38
   PubMed Web of Science ®Google Scholar
• Gompertz S, O'Brien C, Baylery DL, et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-19
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-15
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbations frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
   PubMed Web of Science ®Google Scholar
• Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003;58:589-93
   PubMed Web of Science ®Google Scholar
• Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalized patients with COPD. Eur Respir J 2005;26:234-41
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Pons IS, Mannino DM, et al. Lung function impairment, COPD hospitalizations and subsequent mortality. Thorax 2011;66:585-90
   PubMed Web of Science ®Google Scholar
• Perera PN, Armstrong EP, Sherrill DL, et al. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. COPD 2012;9:131-41
   PubMedGoogle Scholar
• Tashkin DP, Ferguson G. Combination bronchodilator therapy in the management of COPD. Respir Res 2013;14:49
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D. PDE4 inhibitors as potential therapeutic agents in the treatment of COPD – focus on roflumilast. Int J COPD 2007;2:121-9
   Google Scholar
• Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulary potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;197:267-79
   Google Scholar
• Martorana PA, Lunghi B, Lucattelli M, et al. Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med 2008;8:17
   PubMedGoogle Scholar
• Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-53
   PubMed Web of Science ®Google Scholar
• Milara J, Armengot M, Banuls P, et al. Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial cells compromised by cigarette smoke in vitro. Br J Pharmacol 2012;166:2243-62
   PubMed Web of Science ®Google Scholar
• Rall TW. The xanthines. In: Gilman AG, Goodman LS, Gilman A, editors. The pharmacologic basis of therapeutics. Macmillan; New York: 1980. p. 592-607
   Google Scholar
• Bergstrand H. Phosphodiesterase inhibition and theophylline. Eur J Respir Dis 1980;61:37-44
   Google Scholar
• Wouters EFM, Bredenbroker D, Teichmann P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naïve, newly diagnosed type 2 diabetes mellitus. J Clin Endorinol Metab 2012;97:E1720-5
   Web of Science ®Google Scholar
• Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neurtophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62:1081-7
   PubMed Web of Science ®Google Scholar
• Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008;21:616-23
   PubMed Web of Science ®Google Scholar
• Rabe KF, O'Donnel D, Witte S, et al. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2005;366:563-71
   PubMed Web of Science ®Google Scholar
• Calverley PM, Sanchez-Toril F, McIvor A, et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61
   PubMed Web of Science ®Google Scholar
• Rennard SI, Calverley PMA, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res 2011;12:18
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Rabe KF, Goehring U-M, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009;374:685-94
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:418-68
   Web of Science ®Google Scholar
• Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005;2:99-103
   PubMedGoogle Scholar
• Fabbri LM, Calverely PMA, Izquierdo-Alonso JL, et al. Roflumilast in moderat-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomized clinical trials. Lancet 2009;374:695-703
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Rabe K, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest 2013;143:1302-11
   PubMed Web of Science ®Google Scholar
• Oba Y, Lone NA. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 2013;7:13-24
   PubMed Web of Science ®Google Scholar
• Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Pulm Pharmacol Ther 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• FDA Advisory Committee Briefing Document. Daxas® (roflumilast) in Chronic Obstructive Pulmonary Disease. NDA 22-522. Available from: www.fda.gov/AdvisoryCommittees/CommitteesMeeting [Last accessed 7 April 2010]
   Google Scholar
• Center for Drug Evaluation and Research. Application number 0225220)ri9g1s000: medical review(s). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022522Orig1s000MedR.pdf [Last accessed 21 November 2011]
   Google Scholar
• Eschenhagen T. PDE4 in the human heart – major player or little helper? Br J Phamacol 2013;169:524-7
   PubMed Web of Science ®Google Scholar
• White WB, Cooke GE, Kowey PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of chronic obstructive pulmonary disease. Chest 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12
   PubMed Web of Science ®Google Scholar
• Samyshkin Y, Kotachie RW, Mork A-C, et al. Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdon. Eur J Health Econ 2013; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Samyshkin Y, Schlunegger M, Haefliger S, et al. Cost-effectivenss of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J COPD 2013;8:79-87
   Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone proprionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respir Med 2008;102:1099-108
   PubMed Web of Science ®Google Scholar
• Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2009;29:891-905
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
   PubMed Web of Science ®Google Scholar
• Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily anticholinergic bronchodilator. Ann Intern Med 2006;143:317-26
   Web of Science ®Google Scholar
• Calverley PMA, Martinez FJ, Fabbri LM, et al. Does roflumilast decrease exacerbatins in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J COPD 2012;7:375-82
   Google Scholar
• Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:2407-16
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8
   PubMed Web of Science ®Google Scholar
• Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic obstructive pulmonary disease. Am J Health Syst Pharm 2011;68:1221-32
   PubMed Web of Science ®Google Scholar
• Makela MJ, Backer V, Hedegaard M, et al. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013; [Epub ahead of print]
   PubMedGoogle Scholar
• Gross NJ. Novel anti-inflammatory therapies for COPD. Chest 2012;142:1300-7
   PubMed Web of Science ®Google Scholar